Evidence map›Paper›PMID 37380456›Full record

ArticleInternal medicine (Tokyo, Japan)2024

Pembrolizumab-induced Acute Tubulointerstitial Nephritis Accompanying Fanconi Syndrome and Type 1 Renal Tubular Acidosis.

Hayato Fujioka, Kota Kakeshita, Teruhiko Imamura, Yu Arisawa, Shingo Yokoyama, Hidenori Yamazaki, Tsutomu Koike, Takashi Minamisaka, Kenichi Hirabayashi, Koichiro Kinugawa

Open access · diamondAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Hayato FujiokaThe Second Department of Internal Medicine, University of Toyama, Japan.
Kota KakeshitaThe Second Department of Internal Medicine, University of Toyama, Japan.
Teruhiko ImamuraThe Second Department of Internal Medicine, University of Toyama, Japan.
Yu ArisawaThe Second Department of Internal Medicine, University of Toyama, Japan.
Shingo YokoyamaThe Second Department of Internal Medicine, University of Toyama, Japan.
Hidenori YamazakiThe Second Department of Internal Medicine, University of Toyama, Japan.
Tsutomu KoikeThe Second Department of Internal Medicine, University of Toyama, Japan.
Takashi MinamisakaDepartment of Diagnostic Pathology, University of Toyama, Japan.
Kenichi HirabayashiDepartment of Diagnostic Pathology, University of Toyama, Japan.
Koichiro KinugawaThe Second Department of Internal Medicine, University of Toyama, Japan.
University of Toyama · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pembrolizumab, an immune checkpoint inhibitor, is used to treat a variety of refractory malignancies. However, these agents are sometimes associated with immune-related adverse events. A 71-year-old woman received pembrolizumab-integrated chemotherapy to treat her recurrent mandibular gingival cancer. Five months after stopping pembrolizumab, she developed acute tubulointerstitial nephritis associated with Fanconi syndrome and type 1 renal tubular acidosis, which resolved with steroid therapy. We experienced a case of pembrolizumab-induced Fanconi syndrome and type 1 renal acidosis. We recommend follow-up of the tubular function in addition to the renal function even after discontinuation of pembrolizumab.

Indexed as

Acidosis, Renal TubularAntibodies, Monoclonal, HumanizedFanconi SyndromeNephritis, InterstitialAgedFemaleHumansAntibodies, Monoclonal, Humanizedpembrolizumabacute kidney injuryimmune checkpoint inhibitorimmune-related adverse events

Identifiers

PMID37380456
PMCPMC10937132
OpenAlexW4382196954

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.